EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbits

C J Lindo, Peng Liao, Alina Khan, Daivat Bhavsar, Priyanka Srivastava, Julia Glunz, James C Fredenburgh, Andreas Wilmen, Stefan Heitmeier, Jeffrey I Weitz

Journal of Thrombosis and Haemostasis · 2026-06 · 24 (6) · 2179-2188

DOI: 10.1016/j.jtha.2026.02.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-06. Verfasst von C J Lindo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences; Department of Medical Sciences, McMaster Univers…. Hauptthemen laut MEDLINE: Plasminogen, Thrombolytic Therapy, Antibodies, Monoclonal, Fibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Stroke Foundation of Canada, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although fibrinolytic therapy is effective for treating acute myocardial infarction or ischemic stroke, its use is limited by a significant risk of bleeding, highlighting the need for safer alternatives. Antiplasmin serves as the primary endogenous inhibitor of plasmin, thereby protecting fibrin from degradation after plasminogen activation. Inhibition of antiplasmin may enhance fibrinolysis, potentially eliminating the need for exogenous lytic agents such as tissue-type plasminogen activator or tenecteplase. OBJECTIVES: Determine whether BAY3018250, a mAb directed against human and rabbit antiplasmin, accelerates plasminogen activation in vitro and promotes thrombolysis in vivo. METHODS: Binding of BAY3018250 to antiplasmin was determined by surface plasmon resonance, ELISA, and gel electrophoresis. Its effect on plasminogen activation was determined in purified and plasma systems. Lysis of jugular vein thrombi was evaluated in rabbits. RESULTS: BAY3018250 bound antiplasmin with high affinity, decreased plasmin inhibition, blocked the formation of plasmin-antiplasmin complexes, and augmented plasma clot lysis mediated by tissue-type plasminogen activator or tenecteplase. BAY3018250 promoted plasmin generation in human plasma. In rabbits with preformed jugular vein thrombi, administration of BAY3018250 enhanced both endogenous and tenecteplase-induced thrombolysis, without increasing blood loss from standardized ear incisions. Notably, 15 mg/kg BAY3018250 combined with 0.1 mg/kg tenecteplase achieved superior thrombolysis compared with 0.5 mg/kg tenecteplase alone, with no additional risk of bleeding. CONCLUSIONS: These findings indicate that BAY3018250 is a promising candidate for promoting endogenous or plasminogen activator-induced fibrinolysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlasminogenThrombolytic TherapyAntibodies, MonoclonalFibrinolytic Agentsalpha-2-AntiplasminAnimalsRabbitsHumansFibrinolysisFibrinolysinTissue Plasminogen ActivatorMaleJugular Veins

Stichwörter der Autor:innen

SERPINantiplasminfibrinolysisinhibitorthrombolysisthrombosis

Substanzen

PlasminogenFibrinolysinAntibodies, MonoclonalFibrinolytic AgentsTissue Plasminogen Activatoralpha-2-Antiplasmin

Autor:innen und Institutionen

  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences; Department of Medical Sciences, McMaster University, Ontario, Canada.
  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences; Department of Medicine, McMaster University, Ontario, Canada.
  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences; Department of Biochemistry and Biomedical Sciences, McMaster University, Ontario, Canada.
  • Research and Development Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  • Thrombosis and Atherosclerosis Research Institute, McMaster University and Hamilton Health Sciences; Department of Medical Sciences, McMaster University, Ontario, Canada; Department of Medicine, McMaster University, Ont…

Förderung

  • Heart and Stroke Foundation of Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Lindo, C. J., Liao, P., Khan, A., Bhavsar, D., Srivastava, P., Glunz, J., Fredenburgh, J. C., Wilmen, A., Heitmeier, S., & Weitz, J. I. (2026). Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbits. Journal of Thrombosis and Haemostasis, 24(6), 2179-2188. https://doi.org/10.1016/j.jtha.2026.02.022

Vancouver

Lindo CJ, Liao P, Khan A, Bhavsar D, Srivastava P, Glunz J, et al. Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbits. Journal of Thrombosis and Haemostasis. 2026;24(6):2179-2188. doi:10.1016/j.jtha.2026.02.022

BibTeX
@article{Lindo2026,
  author = {Lindo, C J and Liao, Peng and Khan, Alina and Bhavsar, Daivat and Srivastava, Priyanka and Glunz, Julia and Fredenburgh, James C and Wilmen, Andreas and Heitmeier, Stefan and Weitz, Jeffrey I},
  title = {Antibody BAY3018250 against antiplasmin enhances plasminogen activation in vitro and thrombolysis in rabbits},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  volume = {24},
  number = {6},
  pages = {2179--2188},
  doi = {10.1016/j.jtha.2026.02.022}
}
Kostenlos starten →